 The purpose of this study is to evaluate the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk International Prognostic Scoring System1 IPSS myelodysplastic syndrome MDS associated with a del 5q31-33 cytogenetic abnormality. 